US · Healthcare · Biotechnology
EPS came in at -0.65 against a street estimate of -0.51 — a miss of 27.5%.
Analysts rate Immunome Inc a strong buy (15 buy, 1 hold, 0 sell out of 16) with an average price target of $35.19.
| Fund | Stake |
|---|---|
| T. Rowe Price Investment Management,Inc. | 17.35% |
| FMR Inc | 14.98% |
| BlackRock Inc | 7.76% |
| State Street Corp | 4.85% |
| Wellington Management Company LLP | 4.59% |
| Redmile Group, LLC | 4.33% |
| PRIMECAP Management Company | 4.04% |
| Vanguard Capital Management, LLC | 4.01% |
| Document | Date |
|---|---|
| Material agreement · Q4 2026 HEADLINE NUMBERS • On October 2, 2026, Immunome entered into Amendment No. 4 to its license agreement with Bristol-Myers Squibb Company (BMS). • Imm | 2026-10-05 |
| Quarterly report · Q2 2026 IMMUNOME, INC. — FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position declined sharply: Cash and cash equivalents fell from $653.5 million ( | 2026-08-11 |
| Results announced · Q3 2026 IMMUNOME, INC. – Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and marketable securities: $520.0 million as of June 30 | 2026-08-11 |
| Shareholder vote results · Q2 2026 IMMUNOME, INC. - 8-K SUMMARY HEADLINE NUMBERS • Outstanding shares as of record date (April 16, 2026): 113,249,519 shares of common stock • Trading | 2026-06-12 |
| Quarterly report · Q1 2026 IMMUNOME, INC. – 10-Q SUMMARY FOR RETAIL INVESTORS Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Cash position: $582.7 million in cash and ca | 2026-05-12 |
| Results announced · Q2 2026 IMMUNOME, INC. – Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $582.7 million as of March 31, 2026 (down from $653.5 milli | 2026-05-12 |
| Proxy statement · Q2 2026 IMMUNOME, INC. PROXY STATEMENT SUMMARY CEO COMPENSATION & CHANGES • Clay B. Siegall, Ph.D. (Chairman, President, and CEO) total compensation for 202 | 2026-04-24 |
| Annual report FY2025 IMMUNOME, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market Cap (as of June 30, 2025): $728.5 million based on non-affiliate holdin | 2026-03-03 |
Readable in the app.
| Announcement | Date |
|---|---|
| Shares issued to Bristol Myers Squibb under an amended license agreement Immunome disclosed that it issued shares of its stock to Bristol-Myers Squibb (BMS) under a Stock Issuance Agreement dated October 2, 2026. The shares were issued privately under Section 4(a | 2026-10-05 |
| NDA submission planned for 2Q 2026; three IND submissions expected in 2026 Immunome announced strong 2025 results with major progress on its lead cancer drug, varegacestat. The company's Phase 3 trial met its primary goal, showing an 84% reduction in disease progre | 2026-03-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immunome Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.